3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Cholangiocarcinoma
10
Acrocephalosyndactylia
6
Carcinoma, Transitional Cell
5
Neoplasm Metastasis
4
Breast Neoplasms
4
Gastrointestinal Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Stomach Neoplasms
2
Solid Tumor
2
Recurrence
2
Pancreatic Neoplasms
2
Neoplasms
2
Myeloproliferative Disorders
2
Lung Neoplasms
2
Endometrial Neoplasms
2
Colorectal Neoplasms
2
Carcinoma
2
Urinary Bladder Neoplasms
1
Solid Tumor, Miscellaneous
1
Sarcoma
1
Oligodendroglioma
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasms, Unknown Primary
1
Multiple Myeloma
1
Lymphoma, Mantle-Cell
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma, B-Cell
1
Locally Advanced Unresectable Gastric Cancer
1
Liposarcoma
1
Leukemia, Myeloid, Acute
1
Interventions
Temozolomide
73
Radiotherapy
33
Carboplatin
21
Bevacizumab
18
Irinotecan
16
Carmustine
16
Magnetic Resonance Spectroscopy
15
Vincristine
14
Surgical Procedures, Operative
13
Filgrastim
13
Procarbazine
10
Erlotinib Hydrochloride
8
Cyclophosphamide
8
Peripheral Blood Stem Cell Transplantation
7
O(6)-benzylguanine
7
Lomustine
7
Etoposide
7
sargramostim
6
Imatinib Mesylate
6
Flucytosine
6
Cisplatin
6
2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole
6
temsirolimus
5
Vorinostat
5
Thiotepa
5
Radiotherapy, Intensity-Modulated
5
Radiation
5
Biopsy
5
2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide
5
vocimagene amiretrorepvec
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Oligodendroglioma
×
pemigatinib
×
Clear all
NCT05267106
2025-12-30
FIGHT-209
Incyte Corporation
Phase 2
Terminated
83 enrolled
18 charts